Teriparatide in men: Persistence and geographical variation in the UK

Osteoporosis International

Volumn 20, Issue 8, 2009, Pages 1453-1454

  Abhishek, A ^a   Pande, I ^b  

^a DERBYSHIRE ROYAL INFIRMARY   (United Kingdom)

^b NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PARATHYROID HORMONE[1-34];

ADULT; CAUSE OF DEATH; DRUG APPROVAL; DRUG WITHDRAWAL; EUROPE; FOOD AND DRUG ADMINISTRATION; GEOGRAPHIC DISTRIBUTION; HUMAN; KAPLAN MEIER METHOD; LETTER; MAJOR CLINICAL STUDY; MALE; MEN'S HEALTH; NATIONAL HEALTH SERVICE; OSTEOPOROSIS; POSTMENOPAUSE OSTEOPOROSIS; PRESCRIPTION; PRIORITY JOURNAL; SEX DIFFERENCE; TREATMENT OUTCOME; UNITED KINGDOM;

AGED; BONE DENSITY CONSERVATION AGENTS; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; OSTEOPOROSIS; PATIENT DROPOUTS; TERIPARATIDE;

EID: 67650434517     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-008-0788-7     Document Type: Letter

References (5)

1. United States Food and Drugs Agency approval of teriparatide for use in men and postmenopausal women with osteoporosis in 2003. Available at http://www.fda.gov/cder/foi/appletter/2002/21318.pdf
2. European Medicines Agency approval of teriparatide for use in men with osteoporosis in 2007. Available at http://www.emea.europa.eu/ humandocs/Humans/EPAR/forsteo/forsteo.htm
3. NK Arden S Earl DJ Fisher 2006 Persistence with teriparatide in patients with osteoporosis: the UK experience Osteoporos Int 17 1626 1629 (Pubitemid 44477622)
4. National Statistics. UK map collection. NUTS/LAUs area maps-NUTS levels 1-3, LAUs level 1. Available at http://www.statistics. gov.uk /geography/maps.asp
5. National Statistics. Census 2001. National level English regions. Available at http://www.statistics.gov.uk/census2001/pyramids/pages/uk.asp